Show simple item record

dc.contributor.authorTyagi, S.
dc.contributor.authorRibera, A.B.
dc.contributor.authorBannister, R.A.
dc.date.accessioned2020-03-06T20:07:29Z
dc.date.available2020-03-06T20:07:29Z
dc.date.issued2020
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85079755669&doi=10.3389%2ffnmol.2019.00329&partnerID=40&md5=de5a7db47ffdffe5aa086d7f376f39e5
dc.identifier.urihttp://hdl.handle.net/10713/12160
dc.description.abstractThe P/Q-type CaV2.1 channel regulates neurotransmitter release at neuromuscular junctions (NMJ) and many central synapses. CACNA1A encodes the pore-containing α1A subunit of CaV2.1 channels. In humans, de novo CACNA1A mutations result in a wide spectrum of neurological, neuromuscular, and movement disorders, such as familial hemiplegic migraine type 1 (FHM1), episodic ataxia type 2 (EA2), as well as a more recently discovered class of more severe disorders, which are characterized by ataxia, hypotonia, cerebellar atrophy, and cognitive/developmental delay. Heterologous expression of CaV2.1 channels has allowed for an understanding of the consequences of CACNA1A missense mutations on channel function. In contrast, a mechanistic understanding of how specific CACNA1A mutations lead in vivo to the resultant phenotypes is lacking. In this review, we present the zebrafish as a model to both study in vivo mechanisms of CACNA1A mutations that result in synaptic and behavioral defects and to screen for effective drug therapies to combat these and other CaV2.1 channelopathies. Copyright 2020 Tyagi, Ribera and Bannister.en_US
dc.description.sponsorshipThis work was supported by National Institute of Neurological Disorders and Stroke/National Institute of Health (NIH) grants NS103777 and NS086839 to RB and AR, respectively. ST was supported by the Boettcher Foundation.en_US
dc.description.urihttps://doi.org/10.3389/fnmol.2019.00329en_US
dc.language.isoen_USen_US
dc.publisherFrontiers Media S.A.en_US
dc.relation.ispartofFrontiers in Molecular Neuroscience
dc.subjectCaV2.1en_US
dc.subjectchannelopathyen_US
dc.subjectepisodic ataxia type 2en_US
dc.subjectfamilial hemiplegic migraine type 1en_US
dc.subjectP/Q-typeen_US
dc.subjectvertebrate modelsen_US
dc.subjectzebrafishen_US
dc.subjectα1Aen_US
dc.titleZebrafish as a Model System for the Study of Severe CaV2.1 (α1A) Channelopathiesen_US
dc.typeArticleen_US
dc.identifier.doi10.3389/fnmol.2019.00329


This item appears in the following Collection(s)

Show simple item record